Laboratory:Hachioji
- TOP
- tumor-associated test
- tumor-associated antigen
Laboratory:Hachioji
○tumor-associated antigen
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
---|---|---|---|---|---|---|---|
Carcinoembryonic antigen (CEA)
|
Serum
0.4 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
5.0 or less (ng/mL) | |
α-fetoprotein quantification
|
Serum
0.4 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
10.0 or less (ng/mL) | |
Basic fetoprotein (BFP)
|
Serum 0.3 |
S7P ↓ A00 |
|
2-8 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
Less than 75 (ng/mL) | |
Human epididymis protein 4 (HE4)
|
Serum
0.5 |
S09 ↓ A00 |
(21 days) |
2-4 |
CLIA CLIA (Chemiluminescent immunoassay) |
Premenopausal women: 70.0 or less . Postmenopausal women: 140 or less (pmol/L) |
|
CA125
|
Serum
0.4 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
35.0 or less (U/mL) | |
CA15-3
|
Serum
0.4 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
25.0 or less (U/mL) | |
BCA225
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
Less than 160(U/mL) | |
CA19-9
|
Serum
0.4 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
37.0 or less (U/mL) | |
CA72-4
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
ECLIA ECLIA (Electro chemiluminescence immunoassay) |
10.0 or less (U/mL) | |
|
Serum
0.3 |
S09 ↓ A00 |
|
2-4 |
RIA solid phase method IRMA (Immuno radio metric assay) |
45 or less (U/mL) | |
CA54/61
|
Serum
0.5 |
S09 ↓ A00 |
|
3-7 |
ELISA ELISA (Enzyme-Linked immunosorbent assay) |
12 or less (U/mL) | |
DUPAN-2
|
Serum
0.4 |
S09 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
150 or less (U/mL) | |
APOA2 isoform
|
Plasma
0.3 |
PN2,PN5 ↓ A00 |
|
5-7 |
ELISA ELISA (Enzyme-Linked immunosorbent assay) |
APOA2-iIndex 59.5 or more (μg/mL) | |
Sialyl Lexantigen (CSLEX)
|
Serum
0.4 |
S09 ↓ A00 |
|
2-8 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
Less than 8.0 (U/mL) | |
APOA2 isoform
|
Serum
0.3 |
S09 ↓ A00 |
|
5-7 |
ELISA ELISA (Enzyme-Linked immunosorbent assay) |
APOA2-iIndex 59.5 or more (μg/mL) |
|
Sialyl Lex-i antigen (SLX)
|
Serum
0.2 |
S09 ↓ A00 |
|
2-4 |
RIA solid phase method (IRMA) IRMA (Immuno radio metric assay) |
38 or less (U/mL) | |
NCC-ST-439
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
Female Under 49 years old Less than 7.0 Over 50 years old Less than 4.5 Male Less than 4.5 (U/mL) |
|
SPan-1
|
Serum
0.2 |
S09 ↓ A00 |
|
2-4 |
RIA solid phase method (IRMA) IRMA (Immuno radio metric assay) |
30 or less (U/mL) | |
SCC
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
2.5 or less (ng/mL) | |
Prostate-specific antigen (PSA)
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
4.00 or less (ng/mL) | |
PSA F/T ratio
|
Serum
0.8 |
S09 ↓ A00 |
(21 days) |
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
25 (Cutoff value at PSA4.00-10.0ng/mL) (%) | |
γ-seminoprotein (γ-Sm)
|
Serum
0.5 |
S09 ↓ A00 |
(21 days) |
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
4.0 or less (ng/mL) | |
CYFRA (Cytokeratin fragment 19)
|
Serum
0.8 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
3.5 or less (ng/mL) | |
5-S-Cysteinyl dopa (5-S-CD)
|
Serum
1 |
S09 ↓ A00 |
|
3-7 |
HPLC HPLC (High performance liquid chromatography) |
1.5~8.0(nmol/L) | |
Neuron specific enolase (NSE)
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
ECLIA ECLIA (Electro chemiluminescence immunoassay) |
16.3 or less (ng/mL) | |
PIVKA-Ⅱ
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
Less than 40 (mAU/mL) | |
PIVKA-Ⅱ
|
Plasma
0.5 |
PN2,PN5 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
Less than 40 (mAU/mL) | |
Pro-gastrin-releasing peptide (ProGRP)
|
Plasma
0.4 |
PN2,PN5 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
Less than 81 (pg/mL) | |
Anti-p53 antibody
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
1.30 or less (U/mL) | |
Serum HER2 protein
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
CLIA CLIA (Chemiluminescent immunoassay) |
15.2 or less (ng/mL) | |
Soluble mesothelin related peptide
|
Serum
0.3 |
S09 ↓ A00 |
(28 days) |
4-10 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
Less than 1.5 (nmol/L) | |
|
Blood (heparin added)
5 |
PH5 |
|
3-5 |
Flow cytometry(FCM) Flow cytometry |
Negative | |
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
CLIA CLIA (Chemiluminescent immunoassay) |
3.4 or less (ng/mL) | |
|
Serum
0.5 |
S09 ↓ A00 |
|
3-9 |
ELISA ELISA (Enzyme-Linked immunosorbent assay) A method in which after reacting an antigen with a solid-phase antibody, an enzyme-labeled antibody is reacted with the antigen in a secondary reaction, and the enzyme activity is measured by adding a chromogenic substrate. |
63 or less (U/mL) | |
|
Serum
|
S09 ↓ A00 |
|
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
25 (cutoff value in gray zone) (%) | ||
|
Partial urine 5.0 |
U80 |
(21 days) |
2-4 |
ELISA ELISA (Enzyme-Linked immunosorbent assay) A method in which after reacting an antigen with a solid-phase antibody, an enzyme-labeled antibody is reacted with the antigen in a secondary reaction, and the enzyme activity is measured by adding a chromogenic substrate. |
Less than 12.0(U/mL) | |
|
Serum
0.5 |
S09 ↓ A00 |
|
4-6 |
CLIA CLIA (Chemiluminescent immunoassay) |
Less than 75 (U/L) | |
|
Serum
0.5 |
S09 ↓ A00 |
(21 days) |
2-4 | DCAP-P substrate method | 3.2 or less (U/L) |